Home Cart Sign in  
Chemical Structure| 1043444-18-3 Chemical Structure| 1043444-18-3

Structure of Cl-amidine TFA
CAS No.: 1043444-18-3

Chemical Structure| 1043444-18-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cl-amidine is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9±0.3 μM for PAD4.

Synonyms: Cl-amidine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cl-amidine TFA

CAS No. :1043444-18-3
Formula : C16H20ClF3N4O4
M.W : 424.80
SMILES Code : O=C(N)[C@@H](NC(C1=CC=CC=C1)=O)CCCNC(CCl)=N.O=C(O)C(F)(F)F
Synonyms :
Cl-amidine
MDL No. :MFCD31536783
InChI Key :WUSNMVYWOLUWDD-MERQFXBCSA-N
Pubchem ID :57402549

Safety of Cl-amidine TFA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Cl-amidine TFA

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD68+VSMCs 100 µM 0.5 hours Inhibit PAD4 activity, reduce ETs generation Nat Commun. 2022 Dec 6;13(1):7500.
HEK293T/PAD2 cells 25 µM 1 hour To evaluate the target engagement of Cl-amidine TFA in HEK293T/PAD2 cells, results showed that it effectively entered the cells and covalently modified PAD2 at 25 μM concentration. J Med Chem. 2017 Apr 13;60(7):3198-3211.
NZM mouse neutrophils 200 µM 12 hours Cl-amidine inhibited NET release from NZM mouse neutrophils J Clin Invest. 2013 Jul;123(7):2981-93.
BALB/c mouse neutrophils 200 µM 12 hours Cl-amidine inhibited NZM serum-induced NET release from BALB/c mouse neutrophils J Clin Invest. 2013 Jul;123(7):2981-93.
Keratinocytes 0–800 µM 2 days Cl-amidine inhibited deimination in a dose-dependent manner and was not cytotoxic for keratinocytes. At 800 μM, Cl-amidine was shown to reduce deimination by half, alter keratinocyte differentiation, decrease the number of corneocyte layers, significantly increase the number of transitional cells, induce clustering of mitochondria and of heterogeneous vesicles in the cytoplasm of granular keratinocytes, and upregulate the expression of autophagy proteins, including LC3-II, sestrin-2 and p62/SQSTM1. J Invest Dermatol. 2019 Sep;139(9):1889-1897.e4.
Human brain microvascular endothelial cells (HBMVECs) 6 µM 24 hours To assess the direct effect of Cl-amidine on brain endothelial cell PADs, results showed no significant effect of Cl-amidine treatment on vWF release, indicating no citrullination in brain endothelial cells. Nat Cardiovasc Res. 2024 Dec;3(12):1549-1567.
Human brain microvascular endothelial cells (HBMVECs) 500 ng/mL 24-72 hours To assess the effect of NETs on EndMT in brain endothelial cells, results showed that NETs promote EndMT, as evidenced by changes in cell morphology and increased Snail expression. Nat Cardiovasc Res. 2024 Dec;3(12):1549-1567.
MCF7/TamR cells 200 µM 4 days To evaluate the inhibitory effect of Cl-amidine on the proliferation of MCF7/TamR cells, results showed that 200 μM Cl-amidine significantly inhibited cell proliferation J Exp Clin Cancer Res. 2019 Oct 10;38(1):414.
MCF7/TamR cells 50 µM 4 days To evaluate the inhibitory effect of Cl-amidine combined with tamoxifen on the proliferation of MCF7/TamR cells, results showed that 50 μM Cl-amidine combined with 5 μM tamoxifen significantly inhibited cell proliferation J Exp Clin Cancer Res. 2019 Oct 10;38(1):414.
MCF7/TamR cells 25 µM 4 days To evaluate the effect of Cl-amidine combined with docetaxel on the viability of MCF7/TamR cells, results showed that 0.1 μM docetaxel combined with 25 μM Cl-amidine significantly decreased cell viability J Exp Clin Cancer Res. 2019 Oct 10;38(1):414.
U2OS cells 20 µM 72 hours To evaluate the antiproliferative activities of Cl-amidine TFA analogs on U2OS cells. Results showed that biphenyl tetrazole tert-butyl Cl-amidine (13) completely abolished the growth of U2OS cells at 20 μM. J Med Chem. 2015 Feb 12;58(3):1337-44.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Traumatic brain injury model Intraperitoneal injection 10 mg/kg Once daily for three consecutive days Inhibition of PAD4 significantly ameliorated neurological deficits in mice and reduced neuronal pyroptosis by inhibiting the STING/IRE1α-NLRP1 pathway Front Immunol. 2023 Apr 14;14:1125759
NZM mice NZM mouse lupus model Subcutaneous injection 10 mg/kg/d Daily for 14 weeks Cl-amidine significantly improved vasculogenesis, endothelial function, and prothrombotic phenotype in NZM mice J Clin Invest. 2013 Jul;123(7):2981-93.
Mice Ccm3-iECKO mice Intraperitoneal injection 10 mg/kg/day Once daily for 7 days To assess the effect of Cl-amidine on NET formation and CCM lesions, results showed that Cl-amidine significantly reduced NET formation and lesion burden, improving endothelial activation, EndMT, coagulation, and neuroinflammation. Nat Cardiovasc Res. 2024 Dec;3(12):1549-1567.
Pad4−/− mice Citrobacter rodentium infection model Intraperitoneal injection 20 mg/kg Administered 3 hours prior to infection, followed by once daily for the next 3 consecutive days and then once every alternate day until day 11 Cl-amidine treatment modestly enhanced the susceptibility of WT mice to C. rodentium infection, as evidenced by increased CR burden in feces and worsened colonic histopathology, though to a lesser extent compared to Pad4?/? mice and DNase I-treated mice. Mucosal Immunol. 2019 May;12(3):761-771
BALB/c Nude mice Breast cancer xenograft model Intraperitoneal injection 20 mg/kg/day Every 3 days for 3 weeks To evaluate the effect of Cl-amidine combined with docetaxel on tumor growth in a breast cancer xenograft model, results showed that the combination treatment significantly reduced tumor weight J Exp Clin Cancer Res. 2019 Oct 10;38(1):414.
C57BL/6J mice DSS-induced colitis model Gavage 25mg/kg Once daily for 7 days To evaluate the effect of Cl-amidine on DSS-induced colitis, the results showed that Cl-amidine alleviated the severity of colitis, reduced weight loss, decreased the disease activity index (DAI) score, and increased colon length. Front Immunol. 2023 Apr 18;14:1144976
C57BL/6 mice Traumatic brain injury (TBI) model Intraperitoneal injection 50 mg/kg Once daily for three consecutive days Cl-amidine treatment improved short-term neurological functions, reduced cerebral lesion volume, reduced brain edema, and restored cerebral blood flow (CBF) after TBI. In addition, Cl-amidine exerted neuroprotective effects by attenuating BBB disruption, inhibiting immune cell infiltration, and alleviating neuronal death after TBI. J Neuroinflammation. 2023 Sep 30;20(1):222

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.24mL

11.77mL

2.35mL

1.18mL

23.54mL

4.71mL

2.35mL

References

 

Historical Records

Categories